Elodie Coquan

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Yann Vano, Réza Elaidi, Mostefa Bennamoun et al. · The Lancet Oncology · 2022 · 136 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol

Paul Lesueur, Justine Lequesne, Jean‐Michel Grellard et al. · BMC Cancer · 2019 · 116 citations · Full text

Medicine, Oncology, Pharmacology +14

Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial

Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin et al. · Journal of Clinical Oncology · 2023 · 103 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study

Charles Vauchier, Édouard Auclin, Philippe Barthélémy et al. · Journal of Oncology · 2022 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial

Clélia Coutzac, Frédéric Bibeau, Méher Ben Abdelghani et al. · Digestive and Liver Disease · 2022 · 28 citations · Full text

Pharmacy, Immunology, Oncology +17